Sep 30, 2025 10:35 AM Eastern Daylight Time Share FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you suffered losses in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- ...

President Donald Trump will announce on Tuesday that Pfizer plans to lower prices on several of its medications in the United States, a White House official said. ...

AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and a... ...

By Charlie Conchie LONDON (Reuters) -AstraZeneca’s move to upgrade its listing in the U.S. risks pulling liquidity away from London’s stock market and could pave the way for other large companies to follow suit, analysts, investors and advisers said. The British drugmaker, one of London’s most valuable listed companies, said on Monday it would retain its listings in London and Stockholm but also plans to offer its shares directly on the New York Stock Exchange, moving away from the current depositary rec ...

U.S. President Donald Trump speaks during a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025.President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications at lower prices, as his administration pushes to link U.S. drug prices to the cheaper prices paid abroad.Trump will announce a drug pricing deal with Pfizer at 11 a.m. ET, White House spokesperson Kush Desai said in a statement. Pfizer CEO Albert Bourla will be ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi ...

IRVINE, CALIFORNIA - OCTOBER 17: The Johnson & Johnson logo is displayed at company offices on October 17, 2023 in Irvine, California. Johnson & Johnson beat Wall Street’s quarterly revenue and earnings estimates as sales in its pharmaceutical and medical devices businesses grew. (Photo by Mario Tama/Getty Images)Getty ImagesOver the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Vaxcyte (NASDAQ:PCVX) announced a long-term agreement worth up to $1B with Thermo Fisher Scientific (NYSE:TMO) on Tuesday to support the future commercial production of its pneumonia vaccines. Under the agreement, which Vaxcyte (NASDAQ:PCVX) cited as a key component in ...